Clinical Trial

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Study acronym: NeoTHERa
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2026-05-01
Trial Details
NCT Number NCT07220135
Lead Sponsor University of Kansas Medical Center
Conditions Breast Cancer
Enrollment 100 participants
Start Date 2025-11-14
Primary Completion 2027-11-14 (estimated)
Study Completion 2031-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-06